Sensitivity to camptothecin in Aspergillus nidulans identifies a novel gene, scaA+, related to the cellular DNA

G C Bruschi1, C C de Souza, M R Fagundes

  • 1Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Brazil.

Insights

Researchers identified a gene, scaA, involved in cellular sensitivity to the anti-cancer drug camptothecin. This gene

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • Camptothecin is an anti-cancer drug targeting DNA topoisomerase I.
  • Understanding cellular sensitivity to camptothecin requires identifying additional involved factors.
  • Aspergillus nidulans is used as a model organism to study DNA repair and drug sensitivity.

Purpose of the Study:

  • To identify genes mediating cellular sensitivity to camptothecin.
  • To characterize the function of the newly identified scaA gene.
  • To investigate the role of scaA in DNA damage response pathways.

Main Methods:

  • Isolation and characterization of camptothecin-sensitive mutants (sca) in Aspergillus nidulans.
  • Genetic analysis including complementation and gene disruption.
  • Assessment of sensitivity to various DNA damaging agents and cell cycle regulators.

Main Results:

  • Eighteen camptothecin-sensitive mutants were isolated; sca299 exhibited hypersensitivity.
  • The sca299 mutant showed sensitivity to mutagens and actinomycin D, with abnormal nuclear morphology suggesting mitosis with unrepaired DNA damage.
  • Cloning and disruption of the scaA gene revealed its role in sensitivity to camptothecin, berberine, mitomycin C, cis-platinum, and t-butyl hydroperoxide.
  • The scaA gene product shows structural similarity to human nibrin, involved in DNA double-strand break repair.

Conclusions:

  • The scaA gene is crucial for mediating cellular resistance to camptothecin and other DNA damaging agents.
  • The scaA gene product is likely involved in DNA repair pathways, potentially DNA double-strand break repair.
  • scaA represents a novel factor in the cellular response to topoisomerase I-targeting drugs and DNA damage.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...